Happy Thanksgiving? Super Committee Failure Offers Respite For Biopharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The congressional Joint Select Committee on Deficit Reduction’s inability to agree on a plan to cut $1.2 trillion from the federal deficit over 10 years offers a best-case scenario for the biopharmaceutical industry, at least in the near-term.